Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Prokaryotic and viral community structure in the singular chaotropic salt lake Salar de Uyuni.

Ramos-Barbero MD, Martínez JM, Almansa C, Rodríguez N, Villamor J, Gomariz M, Escudero C, Rubin SD, Antón J, Martínez-García M, Amils R.

Environ Microbiol. 2019 Jun;21(6):2029-2042. doi: 10.1111/1462-2920.14549. Epub 2019 Feb 15.

PMID:
30724439
2.

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.

Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S.

Haematologica. 2019 Jan;104(1):113-119. doi: 10.3324/haematol.2018.188888. Epub 2018 Aug 3.

3.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.

N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.

4.

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID.

Eur J Cancer. 2013 Apr;49(6):1287-96. doi: 10.1016/j.ejca.2012.12.010. Epub 2013 Jan 12.

PMID:
23321547
5.

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.

Cristofanilli M, Johnston SR, Manikhas A, Gomez HL, Gladkov O, Shao Z, Safina S, Blackwell KL, Alvarez RH, Rubin SD, Ranganathan S, Redhu S, Trudeau ME.

Breast Cancer Res Treat. 2013 Jan;137(2):471-82. doi: 10.1007/s10549-012-2369-x. Epub 2012 Dec 13.

6.

Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.

Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, Gril B, Hua E, Palmieri D, Polli JW, Castellino S, Rubin SD, Lockman PR, Steeg PS, Smith QR.

Pharm Res. 2012 Mar;29(3):770-81. doi: 10.1007/s11095-011-0601-8. Epub 2011 Oct 20.

7.

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.

Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, Lane SR, Zembryki D, Rubin SD, Winer EP.

J Neurooncol. 2011 Dec;105(3):613-20. doi: 10.1007/s11060-011-0629-y. Epub 2011 Jun 26.

PMID:
21706359
8.

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP.

Clin Cancer Res. 2009 Feb 15;15(4):1452-9. doi: 10.1158/1078-0432.CCR-08-1080.

9.

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, Forster JK, Rubin SD, Stein SH, Burstein HJ.

Ann Oncol. 2009 Jun;20(6):1026-31. doi: 10.1093/annonc/mdn759. Epub 2009 Jan 29.

PMID:
19179558
10.

Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.

Molina JR, Kaufmann SH, Reid JM, Rubin SD, Gálvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM, Mullin RJ, Jewell RC, Felten SJ, Mandrekar S, Adjei AA, Erlichman C.

Clin Cancer Res. 2008 Dec 1;14(23):7900-8. doi: 10.1158/1078-0432.CCR-08-0415.

11.

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.

Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD, Steeg PS.

J Natl Cancer Inst. 2008 Aug 6;100(15):1092-103. doi: 10.1093/jnci/djn216. Epub 2008 Jul 29.

12.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D.

N Engl J Med. 2006 Dec 28;355(26):2733-43. Erratum in: N Engl J Med. 2007 Apr 5;356(14):1487.

13.

Anastrazole and oral contraceptives: a novel treatment for endometriosis.

Amsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE.

Fertil Steril. 2005 Aug;84(2):300-4.

PMID:
16084868
14.

Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels.

Dougherty RH, Rohrer JL, Hayden D, Rubin SD, Leder BZ.

Clin Endocrinol (Oxf). 2005 Feb;62(2):228-35.

PMID:
15670201
15.

Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial.

Plourde PV, Reiter EO, Jou HC, Desrochers PE, Rubin SD, Bercu BB, Diamond FB Jr, Backeljauw PF.

J Clin Endocrinol Metab. 2004 Sep;89(9):4428-33.

PMID:
15356042
16.

Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels.

Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C.

J Clin Endocrinol Metab. 2004 Mar;89(3):1174-80.

PMID:
15001605
17.

Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial.

Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH; McCune-Albright Study Group.

J Pediatr. 2003 Jul;143(1):60-6.

PMID:
12915825
18.

Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease.

Zlatanic J, Korelitz BI, Rajapakse R, Kim PS, Rubin SD, Baiocco PJ, Panagopoulos G.

J Clin Gastroenterol. 2003 Apr;36(4):303-9.

PMID:
12642735
19.

Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up.

Chun A, Chadi RM, Korelitz BI, Colonna T, Felder JB, Jackson MH, Morgenstern EH, Rubin SD, Sacknoff AG, Gleim GM.

Inflamm Bowel Dis. 1998 Aug;4(3):177-81.

PMID:
9741018
20.

Developmental expression of the vav protooncogene.

Bustelo XR, Rubin SD, Suen KL, Carrasco D, Barbacid M.

Cell Growth Differ. 1993 Apr;4(4):297-308.

Supplemental Content

Loading ...
Support Center